ARWR
Arrowhead Pharmaceuticals, Inc. NASDAQ Listed Dec 16, 1993$81.82
After hrs
$81.83
+0.01%
Mkt Cap $11.5B
52w Low $14.30
96.1% of range
52w High $84.55
50d MA $73.79
200d MA $57.84
P/E (TTM)
-6642.6x
EV/EBITDA
61.5x
P/B
21.7x
Debt/Equity
0.8x
ROE
35.6%
P/FCF
69.8x
RSI (14)
56.60
ATR (14)
$4.16
Beta
1.27
50d MA
$73.79
200d MA
$57.84
Avg Volume
1.7M
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
177 East Colorado Boulevard · Pasadena, CA 91105 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -1.09 | -0.93 | +15.1% | 77.95 | -1.9% | -6.7% | +6.9% | +1.7% | -1.5% | +2.3% | — |
| Feb 5, 2026 | AMC | 0.60 | 0.22 | -63.3% | 64.64 | +1.3% | -0.2% | -2.9% | +0.4% | -2.2% | +1.3% | — |
| Nov 25, 2025 | AMC | -0.11 | -0.18 | -61.3% | 46.79 | +1.3% | +23.3% | -8.7% | +6.7% | +3.0% | +12.3% | — |
| Aug 7, 2025 | AMC | -0.94 | -1.26 | -34.0% | 16.06 | -3.2% | +2.2% | +4.8% | +3.4% | +12.3% | -6.1% | — |
| May 12, 2025 | AMC | -0.06 | 2.75 | +4683.3% | 13.97 | +12.7% | +9.4% | -2.4% | +2.9% | +2.4% | +0.2% | — |
| Feb 10, 2025 | AMC | -0.42 | -1.39 | -231.0% | 19.92 | -8.5% | -5.2% | -1.7% | +2.9% | +4.4% | +2.5% | — |
| Nov 26, 2024 | AMC | -1.05 | -1.38 | -31.4% | 21.05 | +6.3% | +24.2% | -0.5% | +1.2% | -1.0% | -11.4% | — |
| Aug 8, 2024 | AMC | -0.58 | -1.38 | -137.9% | 25.85 | -3.3% | -9.4% | -2.0% | -0.3% | -0.7% | -0.2% | — |
| May 9, 2024 | AMC | -0.06 | -1.02 | -1600.0% | 24.72 | +3.1% | -10.7% | -0.1% | +3.9% | +9.3% | -0.2% | — |
| Feb 6, 2024 | AMC | -0.78 | -1.24 | -59.0% | 33.20 | -4.4% | -4.7% | -2.5% | +5.5% | -0.9% | -7.3% | — |
| Nov 29, 2023 | AMC | -0.70 | -1.03 | -47.1% | 28.98 | -3.0% | -26.8% | +9.3% | +7.6% | -6.0% | +1.5% | — |
| Aug 7, 2023 | AMC | -0.58 | -0.96 | -65.5% | 30.81 | -3.8% | -10.8% | +5.5% | -0.1% | -0.4% | +1.9% | — |
| May 2, 2023 | AMC | -0.64 | 0.45 | +170.3% | 35.38 | +6.0% | +13.6% | -0.4% | +3.3% | -2.2% | +0.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | JP Morgan | Initiates | Overweight | $88 | $73.48 | $74.56 | +1.5% | +1.8% | +2.1% | -1.9% | +5.6% | -1.5% |
| Apr 21 | Morgan Stanley | Upgrade | Equal-Weight → Overweight | $100 | $69.25 | $71.93 | +3.9% | +2.6% | +4.0% | +0.6% | -0.7% | -0.4% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $56.27 | $57.29 | +1.8% | +8.0% | +0.0% | -4.9% | -0.2% | +8.8% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $62.64 | $62.68 | +0.1% | +0.4% | -2.2% | +1.3% | +2.3% | -0.2% |
| Jan 22 | B. Riley Securities | Maintains | Buy → Buy | — | $67.60 | $68.95 | +2.0% | +2.9% | -3.6% | -0.3% | +0.1% | -2.0% |
| Jan 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $65.28 | $65.76 | +0.7% | +3.6% | +2.9% | -3.6% | -0.3% | +0.1% |
| Jan 13 | Piper Sandler | Maintains | Overweight → Overweight | — | $65.93 | $66.10 | +0.3% | -0.6% | +0.5% | +0.5% | -3.6% | +2.3% |
| Jan 7 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $70.81 | $66.13 | -6.6% | -7.2% | -1.1% | -0.7% | +2.1% | -0.6% |
| Jan 7 | Goldman Sachs | Maintains | Neutral → Neutral | — | $70.81 | $66.13 | -6.6% | -7.2% | -1.1% | -0.7% | +2.1% | -0.6% |
| Jan 7 | Chardan Capital | Maintains | Buy → Buy | — | $70.81 | $66.13 | -6.6% | -7.2% | -1.1% | -0.7% | +2.1% | -0.6% |
| Dec 17 | Piper Sandler | Maintains | Overweight → Overweight | — | $64.66 | $65.90 | +1.9% | +0.2% | +2.6% | +2.5% | +1.2% | +1.2% |
| Dec 11 | RBC Capital | Maintains | Outperform → Outperform | — | $68.87 | $68.86 | -0.0% | +2.8% | -1.0% | -2.3% | -5.5% | +0.2% |
| Dec 9 | BofA Securities | Maintains | Buy → Buy | — | $68.60 | $65.69 | -4.2% | +0.3% | +0.1% | +2.8% | -1.0% | -2.3% |
| Dec 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $56.25 | $55.91 | -0.6% | +3.0% | +12.3% | -0.6% | -5.0% | +11.7% |
| Dec 1 | Chardan Capital | Maintains | Buy → Buy | — | $52.70 | $52.37 | -0.6% | +6.7% | +3.0% | +12.3% | -0.6% | -5.0% |
| Dec 1 | BofA Securities | Maintains | Buy → Buy | — | $52.70 | $52.37 | -0.6% | +6.7% | +3.0% | +12.3% | -0.6% | -5.0% |
| Nov 26 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $46.79 | $47.39 | +1.3% | +23.3% | -8.7% | +6.7% | +3.0% | +12.3% |
| Nov 20 | Goldman Sachs | Maintains | Neutral → Neutral | — | $38.97 | $39.51 | +1.4% | -2.3% | +6.2% | +9.4% | +5.7% | +23.3% |
| Nov 19 | Piper Sandler | Maintains | Overweight → Overweight | — | $40.47 | $41.06 | +1.5% | -3.7% | -2.3% | +6.2% | +9.4% | +5.7% |
| Nov 19 | Chardan Capital | Maintains | Buy → Buy | — | $40.47 | $41.06 | +1.5% | -3.7% | -2.3% | +6.2% | +9.4% | +5.7% |
| Nov 19 | RBC Capital | Maintains | Outperform → Outperform | — | $40.47 | $41.06 | +1.5% | -3.7% | -2.3% | +6.2% | +9.4% | +5.7% |
| Nov 12 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $41.50 | $41.96 | +1.1% | -0.2% | -0.7% | +0.3% | -2.7% | +0.8% |
| Oct 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.54 | $36.90 | +1.0% | +1.1% | -2.4% | -1.8% | +2.4% | -0.8% |
| Sep 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.03 | $22.73 | +3.2% | +16.6% | +8.3% | +0.7% | +3.9% | -6.6% |
| Aug 11 | Chardan Capital | Maintains | Buy → Buy | — | $16.42 | $16.30 | -0.7% | +4.8% | +3.4% | +12.3% | -6.1% | +9.2% |
| Aug 8 | RBC Capital | Maintains | Outperform → Outperform | — | $16.06 | $15.55 | -3.2% | +2.2% | +4.8% | +3.4% | +12.3% | -6.1% |
| May 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.74 | $15.86 | +0.8% | +3.5% | -6.0% | +0.5% | -1.7% | +1.6% |
| May 13 | Citigroup | Maintains | Neutral → Neutral | — | $13.97 | $15.75 | +12.7% | +9.4% | -2.4% | +2.9% | +2.4% | +0.2% |
| May 13 | Chardan Capital | Maintains | Buy → Buy | — | $13.97 | $15.75 | +12.7% | +9.4% | -2.4% | +2.9% | +2.4% | +0.2% |
| Feb 14 | B. Riley Securities | Maintains | Buy → Buy | — | $19.11 | $19.27 | +0.8% | +4.4% | +2.5% | +3.1% | -0.6% | -5.1% |
| Feb 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.89 | $18.35 | -2.9% | -1.7% | +2.9% | +4.4% | +2.5% | +3.1% |
| Feb 11 | RBC Capital | Maintains | Outperform → Outperform | — | $19.92 | $18.23 | -8.5% | -5.2% | -1.7% | +2.9% | +4.4% | +2.5% |
| Feb 11 | Chardan Capital | Maintains | Buy → Buy | — | $19.92 | $18.23 | -8.5% | -5.2% | -1.7% | +2.9% | +4.4% | +2.5% |
| Jan 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.71 | $20.05 | +1.7% | +9.2% | -3.6% | -2.5% | -1.1% | -0.4% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.76 | $19.71 | -0.3% | -0.3% | +9.2% | -3.6% | -2.5% | -1.1% |
| Dec 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.50 | $19.38 | -0.6% | -0.3% | +1.5% | -0.6% | -0.5% | -2.9% |
| Dec 12 | Chardan Capital | Maintains | Buy → Buy | — | $22.73 | $22.65 | -0.4% | -2.6% | -1.3% | +2.4% | -0.4% | -8.6% |
| Dec 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.34 | $26.27 | -0.3% | -1.0% | -11.4% | -3.5% | +5.9% | -1.4% |
| Nov 29 | Bernstein | Maintains | Market Perform → Market Perform | — | $26.15 | $26.15 | +0.0% | -0.5% | +1.2% | -1.0% | -11.4% | -3.5% |
| Nov 27 | Citigroup | Maintains | Neutral → Neutral | — | $21.05 | $22.37 | +6.3% | +24.2% | -0.5% | +1.2% | -1.0% | -11.4% |
| Nov 27 | Piper Sandler | Maintains | Overweight → Overweight | — | $21.05 | $22.37 | +6.3% | +24.2% | -0.5% | +1.2% | -1.0% | -11.4% |
| Nov 27 | Chardan Capital | Maintains | Buy → Buy | — | $21.05 | $22.37 | +6.3% | +24.2% | -0.5% | +1.2% | -1.0% | -11.4% |
| Nov 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.60 | $18.56 | -0.2% | +0.6% | -2.3% | +1.4% | +1.3% | +12.0% |
| Oct 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.70 | $17.64 | -0.3% | +4.2% | +5.0% | +2.7% | +6.1% | -1.2% |
| Oct 8 | Piper Sandler | Maintains | Overweight → Overweight | — | $18.13 | $18.13 | +0.0% | -0.6% | -1.0% | -0.8% | +4.2% | +5.0% |
| Sep 26 | RBC Capital | Maintains | Outperform → Outperform | — | $19.42 | $19.69 | +1.4% | +1.0% | +0.3% | -1.5% | -1.0% | +0.2% |
| Sep 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.98 | $24.20 | +0.9% | -3.0% | -4.4% | -2.1% | -1.3% | -2.5% |
| Sep 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.83 | $24.02 | +0.8% | -3.9% | +4.7% | -3.0% | -4.4% | -2.1% |
| Aug 12 | B. Riley Securities | Maintains | Buy → Buy | — | $23.41 | $23.43 | +0.1% | -2.0% | -0.3% | -0.7% | -0.2% | +0.2% |
| Jul 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.75 | $28.60 | -0.5% | +0.1% | +0.5% | +0.1% | -2.6% | +1.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 12, 2026 | Lu HongboDir | — | Sell | 2,970 | $76.88 | $228K | 52,012 | -3.79% | -2.13% |
8-K
Madrigal Pharmaceuticals, Inc. -- 8-K Filing
Madrigal Pharmaceuticals reported strong Q1 2026 results for its MASH-focused pipeline, with CEO Bill Sibold signaling positive momentum heading into the year.
May 6
8-K
Unknown — 8-K Filing
This is a routine SEC filing document cover page with standard corporate identification information; it contains no material business updates that would impact ARWR's stock valuation or investor decisions.
Mar 20
8-K
Arrowhead Research Corporation -- 8-K Filing
Arrowhead Pharmaceuticals reported Q1 fiscal 2026 results and is hosting a conference call today, providing investors with updates on financial performance and pipeline progress.
Feb 5
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Avoro Capital Advisors Llc | 10,699,999 | $671M | Added | Mar 2026 |
| 2 | Fmr Llc | 7,266,652 | $456M | Added | Mar 2026 |
| 3 | Vanguard Portfolio Management Llc | 7,146,136 | $448M | New | Mar 2026 |
| 4 | Vanguard Capital Management Llc | 6,032,416 | $378M | New | Mar 2026 |
| 5 | Invesco Ltd. | 3,280,647 | $206M | Added | Mar 2026 |
| 6 | Morgan Stanley | 2,952,010 | $196M | Reduced | Dec 2025 |
| 7 | Northern Trust Corp | 1,655,837 | $104M | Added | Mar 2026 |
| 8 | Deerfield Management Company, L.p. | 1,573,297 | $99M | Reduced | Mar 2026 |
| 9 | Janus Henderson Group Plc | 1,436,990 | $90M | New | Mar 2026 |
| 10 | Ubs Group Ag | 1,336,271 | $84M | Added | Mar 2026 |
| 11 | D.e. Shaw & Co | 1,183,838 | $74M | Added | Mar 2026 |
| 12 | Pictet Asset Management Holding Sa | 1,028,736 | $69M | Added | Dec 2025 |
| 13 | Bank Of America Corp /de/ | 1,064,455 | $67M | Added | Mar 2026 |
| 14 | Hood River Capital Management Llc | 1,056,534 | $66M | New | Mar 2026 |
| 15 | Renaissance Technologies Llc | 1,036,495 | $65M | New | Mar 2026 |
| 16 | Bank Of New York Mellon Corp | 960,144 | $60M | Added | Mar 2026 |
| 17 | Western Financial Corp/ca | 820,239 | $54M | — | Dec 2025 |
| 18 | Principal Financial Group Inc | 715,539 | $48M | Reduced | Dec 2025 |
| 19 | Connor, Clark & Lunn Investment Management Ltd. | 663,262 | $44M | Added | Dec 2025 |
| 20 | Bnp Paribas Financial Markets | 650,599 | $41M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$11.52B
Enterprise Value
$10.14B
P/E (TTM)
-6642.62x
Forward P/E
—
PEG Ratio
28.35x
P/B
21.74x
P/S
13.19x
P/FCF
69.76x
EV/EBITDA
61.49x
Shares Out
133.8M
Financials (TTM)
Revenue
$829.4M
Net Income
-$1.6M
EBITDA
$164.8M
Free Cash Flow
$156.9M
Op Cash Flow
$179.6M
EPS Basic
$-0.01
EPS Diluted
$-0.01
EPS Forward
$-3.38
Gross Margin
97.1%
Op Margin
11.9%
Net Margin
-0.2%
Balance Sheet
Total Assets
$1.39B
Total Liab.
$881.9M
Total Equity
$503.4M
Cash
$919.4M
LT Debt
$214.9M
Book Value/Sh
$3.76
Debt/Equity
0.79x
Current Ratio
4.86
Quick Ratio
4.86
Returns & Growth
ROE
35.6%
ROA
12.6%
ROIC
4.7%
Rev Growth YoY
+23258.2%
EPS Growth YoY
+99.8%
Price Returns
2W
-2.2%
1M
+6.0%
3M
+23.1%
6M
+47.8%
12M
+384.8%
Technicals
52W High
$84.55
52W Low
$14.30
50d MA
$73.79
200d MA
$57.84
RSI (14)
56.60
ATR (14)
$4.16
Beta
1.27
Avg Volume
1.7M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$81.22
High
$110.00
Low
$35.00
Median
$81.00
Data updated apr 24, 2026 7:06pm
· Source: financialmodelingprep.com